Viridian Therapeutics, Inc.

As of June 30, 2026, Viridian Therapeutics, Inc. carries a market capitalization of 2.14B, placing it among publicly traded companies globally. Its enterprise value stands at 1.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Viridian Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Viridian Therapeutics, Inc. has 113.24M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 25.63, and the price-to-book ratio stands at 3.79.

These figures are as of June 30, 2026. The EV/Sales ratio of 21.04 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.50B versus a market cap of 2.14B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Viridian Therapeutics, Inc. maintains a current ratio of 16.95, meaning it holds 16.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 36.68, indicating elevated leverage, while an interest coverage ratio of -25.93 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Viridian Therapeutics, Inc. posted a negative return on equity (ROE) of -86.93, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -46.08, reflecting losses generated across the asset base. The company generates approximately 316,471.64 in revenue per employee across its workforce of 224.75, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Viridian Therapeutics, Inc.'s stock has gained approximately 4.31% over the past 52 weeks. The 50-day moving average sits at 21.58, while the 200-day moving average is 22.18.

Over the twelve months ended June 30, 2026, Viridian Therapeutics, Inc. generated 71.13M in revenue and converted that into -386.97M in net income, yielding earnings per share of -4.01. EBITDA reached -404.73M, while operating income came in at -405.20M.

As of June 30, 2026, Viridian Therapeutics, Inc. holds 981.53M in cash and equivalents against 242.88M in total debt, resulting in a net debt position of 77.17M. Total book value stands at 564.07M, with working capital of 1.02B providing operational flexibility.

Viridian Therapeutics, Inc. produced -333.34M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.70M in capital expenditures, free cash flow totaled -335.04M - equivalent to -3.47 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -569.68 and net profit margin of -544.06 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -18.38: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -35.01, meaning Viridian Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Viridian Therapeutics, Inc.'s most recent stock split took place on November 13, 2020 with a 15:1 split ratio.

As of June 30, 2026, Viridian Therapeutics, Inc. has an Altman Z-Score of 0.88, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.